Scientific and Regulatory Policy Committee Brief Communication: 2019 Survey on Use of Digital Histopathology Systems in Nonclinical Toxicology Studies.

GLP Scientific and Regulatory Policy Committee digital histopathology peer review toxicology whole-slide image

Journal

Toxicologic pathology
ISSN: 1533-1601
Titre abrégé: Toxicol Pathol
Pays: United States
ID NLM: 7905907

Informations de publication

Date de publication:
04 2022
Historique:
pubmed: 25 3 2022
medline: 25 5 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

Histopathologic evaluation and peer review using digital whole-slide images (WSIs) is a relatively new medium for assessing nonclinical toxicology studies in Good Laboratory Practice (GLP) environments. To better understand the present and future use of digital pathology in nonclinical toxicology studies, the Society of Toxicologic Pathology (STP) formed a working group to survey STP members with the goal of creating recommendations for implementation. The survey was administered in December 2019, immediately before the COVID-19 pandemic, and the results suggested that the use of digital histopathology for routine GLP histopathology assessment was not widespread. Subsequently, in follow-up correspondence during the pandemic, many responding institutions either began investigating or adopting digital WSI systems to reduce employee exposure to COVID-19. Therefore, the working group presents the survey results as a pre-pandemic baseline data set. Recommendations for use of WSI systems in GLP environments will be the subject of a separate publication.

Identifiants

pubmed: 35321602
doi: 10.1177/01926233221084621
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

397-401

Auteurs

Thomas Forest (T)

Merck & Co., Inc., West Point, Pennsylvania, USA.

Famke Aeffner (F)

Amgen, Inc., San Francisco, California, USA.

Dinesh S Bangari (DS)

Sanofi R&D, Framingham, Massachusetts, USA.

Bhupinder Bawa (B)

AbbVie, Inc., Chicago, Illinois, USA.

Jonathan Carter (J)

Labcorp Early Development Laboratories Ltd, Harrogate, UK.

James Fikes (J)

Biogen, Inc., Cambridge, Massachusetts, USA.

Wanda B High (WB)

High Preclinical Pathology Consulting, Rochester, New York, USA.

Shim-Mo Hayashi (SM)

Tokyo University of Agriculture and Technology, Fuchu, Japan.
National Institute of Health Sciences, Kawasaki, Japan.

LuAnn McKinney (L)

US Food and Drug Administration, Silver Spring, Maryland, USA.

Daniel Rudmann (D)

Charles River Laboratories International, Inc., Wilmington, Massachusetts, USA.

Thomas Steinbach (T)

Experimental Pathology Laboratories, Inc., Research Triangle Park, North Carolina, USA.

Vanessa Schumacher (V)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Oliver C Turner (OC)

Novartis, East Hanover, New Jersey, USA.

Jerrold M Ward (JM)

Global VetPathology, Montgomery Village, Maryland, USA.

Cynthia J Willson (CJ)

Inotiv-RTP, Research Triangle Park, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH